The first stop for professional medicines advice

Mercaptamine

Published
Topics: CCG commissioned new medicinesEyes and visionHaematological disorders · MercaptamineNew MedicinesNutritional and metabolic disordersPatent expiriesSafety in BreastfeedingStability in dosette boxes ·
Contents
  1. dm+d
  2. Refrigerated Storage
    1. Cystadrops · Recordati Rare Diseases UK
    2. Procysbi · Chiesi Ltd
  3. Medicine Compliance Aid Stability
    1. Cystagon · Recordati Rare Diseases UK Ltd
  4. Lactation Safety Information
    1. Cysteamine for nephropathic cystinosis

dm+d

109109007

Refrigerated Storage

CystadropsRecordati Rare Diseases UK

Recordati Rare Diseases UK
Cystadrops
Eye drops solution, 3.8 mg/mL

In the event of an inadvertent temperature excursion the following data may be used:
In-house stability data from the manufacturer for this product support, that continuous or episodic exposure to temperatures stated below does not affect the quality of the product nor will the exposure reduce the total shelf life of the products.
-20°C to 2°C for a period of time up to 7 days
8°C to 15°C for a period of time up to 7 days
15°C to 25°C for a period of time up to 3 days

Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

20 January 2022
London MI Service

ProcysbiChiesi Ltd

Chiesi Ltd
Procysbi
25mg and 75mg gastro-resistant hard capsules

Contact Chiesi Ltd in all cases where a deviation from the recommended storage conditions has occurred.

Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk

21 October 2021
London MI Service

Medicine Compliance Aid Stability

CystagonRecordati Rare Diseases UK Ltd

Recordati Rare Diseases UK Ltd
Cystagon
Capsules 50mg, 150mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Packaging includes a dessicant.
19 August 2022
Usage of Medicines in Compliance Aids

Lactation Safety Information

Cysteamine for nephropathic cystinosis

Cysteamine for nephropathic cystinosis
No
No published evidence of safety
High dose animal studies have shown serious adverse effects in breastfed young animals. The relevance of this to human breast milk is unknown
Safety in Lactation: Metabolic disorders
24 September 2020